FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility study
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Treatment consisted of modified mFOLFOX6 plus bevacizumab alternated biweekly with 5-FU/LV (simplified LV5FU2) plus bevacizumab. Treatment was administered until tumor progression, unacceptable toxicity or patient refusal. Primary outcome(s): Response rate Safety Study Design: Single arm Non-randomized
创建时间：
2010-04-15
